TACE as an Adjuvant Therapy After Hepatectomy for HCC
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Investigators hypothesise that the use of transarterial chemoembolisation (TACE) after liver
resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in
the liver and thus improve survival of patients with high risk factors for residual tumor.
The aim of this study is to compare the survival of patients with high risk factors for
residual tumor undergoing liver resection plus post-operative TACE versus liver resection
alone.